Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are use...

Descripción completa

Detalles Bibliográficos
Autores principales: Neupane, Karun, Wahab, Ahsan, Masood, Adeel, Faraz, Tehniat, Bahram, Saman, Ehsan, Hamid, Hannan, Abdul, Anwer, Faiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257048/
https://www.ncbi.nlm.nih.gov/pubmed/34234609
http://dx.doi.org/10.2147/JBM.S317966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257048/
https://www.ncbi.nlm.nih.gov/pubmed/34234609
http://dx.doi.org/10.2147/JBM.S317966

Ejemplares similares